Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

22.58 -0.47 (-2.04%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

APLS Investor Alert: Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Announce the Filing of a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.

August 02, 2023

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

August 01, 2023

On Tuesday, 46 stocks hit new 52-week lows.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2023 ↗

August 01, 2023

Via Benzinga

Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session ↗

July 31, 2023

Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report.

Via Benzinga

Apellis Crashes As Safety Issues Outweigh Massive Eye-Drug Sales Beat ↗

July 31, 2023

Apellis crashed after Syfovre safety issues continued to plague the stock.

Via Investor's Business Daily

Stocks That Hit 52-Week Lows On Monday ↗

July 31, 2023

On Monday, 27 stocks hit new 52-week lows.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 31, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 31, 2023

Via Benzinga

Rising Stars, Falling Trends: July's Industry ETF Winners And Losers ↗

July 31, 2023

Via Benzinga

Apellis Pharmaceuticals Stock Slips Despite Q2 Sales Beat Thanks To Syfovre, Empaveli ↗

July 31, 2023

Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported a second quarter (Q2) EPS loss of $1.02, beating the

Via Benzinga

Why China Natural Resources Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket ↗

July 31, 2023

Gainers

Via Benzinga

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

July 31, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

July 30, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For July 31, 2023 ↗

July 31, 2023

Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million.

Via Benzinga

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

July 29, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 28, 2023

Via Benzinga

Alphabet, Boeing, Union Pacific And Other Big Stocks Moving Higher On Wednesday ↗

July 26, 2023

U.S. stocks traded mixed, with the Dow Jones gaining around 50 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 28, 2023

Friday's session saw 59 companies set new 52-week lows.

Via Benzinga

Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown ↗

July 25, 2023

The FDA approved Tarsus Pharmaceuticals Inc's (NASDAQ: TARS) Xdemvy (lotilaner ophthalmic solution) 0.25% for

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

July 25, 2023

On Tuesday, 56 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

July 26, 2023

Wednesday saw 59 companies set new 52-week lows.

Via Benzinga

Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results

July 24, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

July 24, 2023

On Monday morning, 70 companies achieved new lows for the year.

Via Benzinga

Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review ↗

July 21, 2023

But all the major indexes are at or near 15-month highs.

Via Investor's Business Daily

APLS Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Investors

July 21, 2023

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

July 20, 2023

During Thursday's session, 40 stocks hit new 52-week lows.

Via Benzinga

Apellis's Stock Under Pressure On Syfovre Safety Concerns: Analyst Slashes Price Target ↗

July 20, 2023

Since Friday, Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares have plummeted around 50% after the stock came under pressure following the disclosure of

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 20, 2023

Via Benzinga

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – APLS

July 18, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

July 18, 2023

During Tuesday's trading, 46 companies set new 52-week lows.

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.